Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

New England Journal of Medicine

Volumn 346, Issue 9, 2002, Pages 645-652

  Kantarjian, Hagop ^a   Sawyers, Charles ^b   Hochhaus, Andreas ^c   Guilhot, Francois ^d   Schiffer, Charles ^e   Gambacorti Passerini, Carlo ^f   Niederwieser, Dietger ^g   Resta, Debra ^h,i   Capdeville, Renaud ^h,i   Zoellner, Ulrike ^h,i   Talpaz, Moshe ^a   Druker, Brian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e WAYNE STATE UNIVERSITY   (United States)

^f SAN GERARDO HOSPITAL   (Italy)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ Oregon Health Sciences University ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER GRADING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CYTOGENETICS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROGNOSIS; PYRIMIDINES; REGRESSION ANALYSIS;

EID: 0037186915     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011573     Document Type: Article

References (26)

1. Chronic myeloid leukemia
2. Chronic myelogenous leukemia: Biology and therapy
3. Chronic myelogenous leukemia: A concise update
4. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period
5. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia
6. Staging and prognosis in chronic myelogenous leukemia
7. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
8. A minute chromosome in human chronic granulocytic leukemia
9. Acute leukaemia in bcr/abl transgenic mice
10. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
11. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
12. Bcr/abl, the hallmark of chronic myeloid leukemia in man, induces multiple haematopoietic neoplasms in mice
13. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
14. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alfa and low-dose cytarabine
15. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
16. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
17. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
18. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
19. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
20. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
21. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
22. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
23. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
24. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
25. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia
26. Chronic myeloid leukemia: Current treatment options